327 related articles for article (PubMed ID: 36699696)
1. Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?
Martins-Lima C; Chianese U; Benedetti R; Altucci L; Jerónimo C; Correia MP
Front Mol Biosci; 2022; 9():1070383. PubMed ID: 36699696
[TBL] [Abstract][Full Text] [Related]
2. Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression.
Martins-Lima C; Miranda-Gonçalves V; Lobo J; Constâncio V; Leite-Silva P; Guimarães-Teixeira C; Monteiro-Reis S; Sequeira JP; Cantante M; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Cell Oncol (Dordr); 2022 Feb; 45(1):135-149. PubMed ID: 35064910
[TBL] [Abstract][Full Text] [Related]
3. Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response.
Annels NE; Simpson GR; Pandha H
Front Oncol; 2020; 10():175. PubMed ID: 32133299
[TBL] [Abstract][Full Text] [Related]
4. An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer.
Xiao Z; Cai Z; Deng D; Tong S; Zu X
Front Immunol; 2022; 13():1000321. PubMed ID: 36211349
[TBL] [Abstract][Full Text] [Related]
5. The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition.
Gómez-Valenzuela F; Escobar E; Pérez-Tomás R; Montecinos VP
Front Oncol; 2021; 11():686792. PubMed ID: 34178680
[TBL] [Abstract][Full Text] [Related]
6. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
7. The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis.
Du Y; Miao W; Jiang X; Cao J; Wang B; Wang Y; Yu J; Wang X; Liu H
Front Oncol; 2021; 11():683951. PubMed ID: 34150647
[TBL] [Abstract][Full Text] [Related]
8. Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition.
Monteiro-Reis S; Miranda-Gonçalves V; Guimarães-Teixeira C; Martins-Lima C; Lobo J; Montezuma D; Dias PC; Neyret-Kahn H; Bernard-Pierrot I; Henrique R; Jerónimo C
Int J Biol Sci; 2023; 19(1):1-12. PubMed ID: 36594099
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
Singh R; Singh UP; Agrawal V; Garg M
Mol Biol Rep; 2022 Aug; 49(8):7541-7556. PubMed ID: 35593896
[TBL] [Abstract][Full Text] [Related]
10. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
Liu Y; Wu Y; Zhang P; Xu C; Liu Z; He C; Liu Y; Kang Z
Front Oncol; 2021; 11():636870. PubMed ID: 33747959
[TBL] [Abstract][Full Text] [Related]
11. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
12. AIM2 inflammasome activation benefits the therapeutic effect of BCG in bladder carcinoma.
Zhou H; Zhang L; Luo W; Hong H; Tang D; Zhou D; Zhou L; Li Y
Front Pharmacol; 2022; 13():1050774. PubMed ID: 36386141
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
14. An EMT-related gene signature for the prognosis of human bladder cancer.
Cao R; Yuan L; Ma B; Wang G; Qiu W; Tian Y
J Cell Mol Med; 2020 Jan; 24(1):605-617. PubMed ID: 31657881
[TBL] [Abstract][Full Text] [Related]
15. Role of tumor microenvironment in the efficacy of BCG therapy.
Ibrahim OM; Pandey RK; Chatta G; Kalinski P
Trends Res; 2020 Oct; 3(4):. PubMed ID: 33178990
[TBL] [Abstract][Full Text] [Related]
16. TGF-β-induced transgelin promotes bladder cancer metastasis by regulating epithelial-mesenchymal transition and invadopodia formation.
Chen Z; He S; Zhan Y; He A; Fang D; Gong Y; Li X; Zhou L
EBioMedicine; 2019 Sep; 47():208-220. PubMed ID: 31420300
[TBL] [Abstract][Full Text] [Related]
17. BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.
Rouanne M; Adam J; Radulescu C; Letourneur D; Bredel D; Mouraud S; Goubet AG; Leduc M; Chen N; Tan TZ; Signolle N; Bigorgne A; Dussiot M; Tselikas L; Susini S; Danlos FX; Schneider AK; Chabanon R; Vacher S; Bièche I; Lebret T; Allory Y; Soria JC; Arpaia N; Kroemer G; Kepp O; Thiery JP; Zitvogel L; Marabelle A
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503263
[TBL] [Abstract][Full Text] [Related]
18. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of a Stromal EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome.
Du Y; Wang B; Jiang X; Cao J; Yu J; Wang Y; Wang X; Liu H
Front Oncol; 2021; 11():620674. PubMed ID: 33747932
[TBL] [Abstract][Full Text] [Related]
20. The Bladder Microbiome Is Associated with Epithelial-Mesenchymal Transition in Muscle Invasive Urothelial Bladder Carcinoma.
Li WT; Iyangar AS; Reddy R; Chakladar J; Bhargava V; Sakamoto K; Ongkeko WM; Rajasekaran M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
